I am still a bit bemused by the wording of the announcement.
”FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission”
Note - not “data”, not “new information”, but “consideration”.
Were the FDA head honchos having a round of golf, and decided amongst themselves that they had been a bit hard on the Aussie battler? Then back to the clubhouse for a scotch or three.
Or perhaps Big Pharma have “advised” the FDA top order that Meso's gonads have been squeezed enough, so give them a win that also allows BP to make a cheap TO?
Don't get me wrong. My wife is very happy to see the reverse in fortunes, and so quick after that dilutive capital raise too!
- Forums
- ASX - By Stock
- MSB
- Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-451
-
-
- There are more pages in this discussion • 646 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.00 |
Change
-0.005(0.50%) |
Mkt cap ! $1.096B |
Open | High | Low | Value | Volume |
$1.00 | $1.01 | 94.0¢ | $6.616M | 6.826M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 118621 | 99.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.00 | 55631 | 14 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 114050 | 0.995 |
16 | 137330 | 0.990 |
18 | 258958 | 0.985 |
12 | 97924 | 0.980 |
7 | 91565 | 0.975 |
Price($) | Vol. | No. |
---|---|---|
1.000 | 46108 | 9 |
1.005 | 258485 | 12 |
1.010 | 83006 | 11 |
1.015 | 42929 | 4 |
1.020 | 213278 | 6 |
Last trade - 12.25pm 31/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online